Scholarlink

Background <p>Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.</p> Methods <p>PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025. Outcomes assessed included monthly migraine and headache day change from baseline at 12 weeks, ≥ 50% reduction in monthly migraine days (MMD), acute medication use days at 12 weeks, treatment-emergent adverse events (TEAE), score on Role Function-Restrictive domain of MSQ at 12 weeks, score on daily activity performance and physical impairment domains of AIM-D at 12 weeks. Subgroup analysis was performed based on different doses of atogepant.</p> Results <p>Six RCTs comprising of 4052 patients were included. Atogepant showed significant improvement in patients with migraine in terms of MMD over 12 weeks at all doses, 10&#xa0;mg, 30&#xa0;mg, and 60&#xa0;mg. Moreover, it also reduced monthly headache days, had 50% reduction in MMD, and reduced days requiring acute medication use. Atogepant was shown to increase the risk of TEAE, particularly gastrointestinal (GI) side effect including constipation and nausea, however, occurrence of other side effects with atogepant use was insignificant.</p> Conclusion <p>Atogepant is a highly effective CGRP antagonist for migraine prevention, however, it is associated with increased incidence of GI side effects. Further studies are needed to comprehensively investigate the relationship between atogepant dosage and migraine improvement and safety profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of Atogepant in migraine prevention: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月2日

查看全文
  • Naresh Kumar Ladhwani,
  • Priya Bai,
  • Rohan Lal,
  • Aresha Masood Shah,
  • Sheela Bai,
  • Ghazi Uddin Ahmed,
  • Rimsha Zameer,
  • Varisha Fatima Shaikh,
  • Arsalan Hyder,
  • Sikander Ali,
  • Muhammad Hamza Beg,
  • Maheen Adeeb,
  • Mahir Tesfaye

摘要

Background

Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.

Methods

PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025. Outcomes assessed included monthly migraine and headache day change from baseline at 12 weeks, ≥ 50% reduction in monthly migraine days (MMD), acute medication use days at 12 weeks, treatment-emergent adverse events (TEAE), score on Role Function-Restrictive domain of MSQ at 12 weeks, score on daily activity performance and physical impairment domains of AIM-D at 12 weeks. Subgroup analysis was performed based on different doses of atogepant.

Results

Six RCTs comprising of 4052 patients were included. Atogepant showed significant improvement in patients with migraine in terms of MMD over 12 weeks at all doses, 10 mg, 30 mg, and 60 mg. Moreover, it also reduced monthly headache days, had 50% reduction in MMD, and reduced days requiring acute medication use. Atogepant was shown to increase the risk of TEAE, particularly gastrointestinal (GI) side effect including constipation and nausea, however, occurrence of other side effects with atogepant use was insignificant.

Conclusion

Atogepant is a highly effective CGRP antagonist for migraine prevention, however, it is associated with increased incidence of GI side effects. Further studies are needed to comprehensively investigate the relationship between atogepant dosage and migraine improvement and safety profile.